ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2022 Aug 8

PMID 35937390

Authors

Juan Li

Dong Yang

Cong Zhang

Sisi Wei

Ruinian Zhao

Suli Dai

Baoen Shan

Affiliations

Soon will be listed here.

Abstract

Objective: Endothelial cell-specific molecule 1 (ESM1) has been implicated as an oncogene in several types of cancer. However, the potential role of ESM1 in esophageal carcinogenesis (ESCA)/esophageal squamous cell carcinoma (ESCC) is still unclear.

Methods: The expression, function, and survival data of ESM1 were observed using a bioinformatics approach. Subsequently, the expression level of ESM1 in surgical esophageal tumors and adjacent normal tissues was detected by qRT-PCR and immunofluorescence. We further revealed protein expression by immunohistochemistry (IHC), which is related to the prognosis of patients with ESCC using survival analysis. In vitro, knockdown of ESM1 in KYSE150 and KYSE510 cell lines, colony formation assays, wound healing assays, and Transwell assays were performed.

Results: ESM1 is significantly elevated in 12 of 20 types of human cancer. ESM1 is highly expressed in tumor tissue compared with adjacent normal tissue and was identified as a hub gene in ESCA. Clinical outcome endpoints of overall survival (OS), progression-free interval (PFI), and disease-specific survival (DSS) curves showed that patients whose ESM1 expression was high had a lower clinical survival rate. The ESM1 high-expression group has a certain correlation with clinical stage and grade. The IHC of ESM1 further demonstrated that the higher the expression was, the worse the N classification and pTNM stage in patients with ESCC, which had a distinctly poorer overall 5-year survival rate. Univariate analysis showed that age, N classification, pTNM stage, and ESM1 expression were all prognostic factors, although multivariate Cox regression analysis showed that only pTNM stage was an independent prognostic factor. In vitro, silencing ESM1 suppressed the proliferation, migration, and invasion of KYSE150 and KYSE510 cells.

Conclusions: ESM1 is a hub gene in the initiation and progression of ESCA/ESCC that promotes the proliferation, migration, and invasion of esophageal cancer cells and may be a promising therapeutic target and prognostic indicator.

Citing Articles

ESM1 promote proliferation, invasion and angiogenesis via Akt/mTOR and Ras pathway in kidney renal clear cell carcinoma.

Luo J, Yi T, Wang Y, Song W, Gao Z, Wang J Sci Rep. 2025; 15(1):4902.

PMID: 39929852 PMC: 11811180. DOI: 10.1038/s41598-024-82400-z.

ESM1 May Be Used as a New Indicator for the Diagnosis and Prognosis of Early and Advanced Stage Digestive Tract Cancers.

Kang K, Wang Y, Zhang B, Xie Z, Qing S, Di Y Int J Gen Med. 2024; 17:2809-2820.

PMID: 38912330 PMC: 11193464. DOI: 10.2147/IJGM.S456973.

Roles of endothelial cell specific molecule‑1 in tumor angiogenesis (Review).

Zhou J, Zhou P, Wang J, Song J Oncol Lett. 2024; 27(3):137.

PMID: 38357478 PMC: 10865172. DOI: 10.3892/ol.2024.14270.

Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer.

Adzibolosu N, Alvero A, Ali-Fehmi R, Gogoi R, Corey L, Tedja R Front Immunol. 2023; 14:1204148.

PMID: 37435088 PMC: 10331425. DOI: 10.3389/fimmu.2023.1204148.

References

Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A . Overexpression of endocan induces tumor formation. Cancer Res. 2003; 63(18):6084-9. View

Friedrichs K, Gluba S, Eidtmann H, Jonat W . Overexpression of p53 and prognosis in breast cancer. Cancer. 1993; 72(12):3641-7. DOI: 10.1002/1097-0142(19931215)72:12<3641::aid-cncr2820721215>3.0.co;2-8. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Kocarnik J, Compton K, Dean F, Fu W, Gaw B, Harvey J . Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2021; 8(3):420-444. PMC: 8719276. DOI: 10.1001/jamaoncol.2021.6987. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Kang Y, Ji N, Han S, Lee C, Kim J, Yeom Y . ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer. Cell Signal. 2012; 24(10):1940-9. DOI: 10.1016/j.cellsig.2012.06.004. View

Rebollo J, Geliebter J, Reyes N . ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells. Int J Biomed Sci. 2017; 13(1):35-42. PMC: 5422643. View

Youssef A, Issa H, Omar M, Behiry E, Elfallah A, Hasaneen A . Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality. Clin Exp Gastroenterol. 2018; 11:431-438. PMC: 6260127. DOI: 10.2147/CEG.S171339. View

Hopper A, Campbell J . Early diagnosis of oesophageal cancer improves outcomes. Practitioner. 2016; 260(1791):23-8, 3. View

10.

Lassalle P, Molet S, Janin A, Heyden J, Tavernier J, Fiers W . ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996; 271(34):20458-64. DOI: 10.1074/jbc.271.34.20458. View

11.

De Freitas Caires N, Gaudet A, Portier L, Tsicopoulos A, Mathieu D, Lassalle P . Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018; 22(1):280. PMC: 6204032. DOI: 10.1186/s13054-018-2222-7. View

12.

Cox L, van Eijk L, Ramakers B, Dorresteijn M, Gerretsen J, Kox M . Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015; 43(4):322-6. DOI: 10.1097/SHK.0000000000000320. View

13.

Mihajlovic D, Lendak D, Brkic S, Draskovic B, Mitic G, Novakov Mikic A . Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014; 93:92-7. DOI: 10.1016/j.mvr.2014.04.004. View

14.

Tsai J, Zhang J, Minami T, Voland C, Zhao S, Yi X . Cloning and characterization of the human lung endothelial-cell-specific molecule-1 promoter. J Vasc Res. 2002; 39(2):148-59. DOI: 10.1159/000057763. View

15.

Dennis Jr G, Sherman B, Hosack D, Yang J, Gao W, Lane H . DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3. View

16.

Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A . Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res. 2007; 313(7):1285-94. DOI: 10.1016/j.yexcr.2007.01.021. View

17.

Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T . Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006; 34(2):532-7. DOI: 10.1097/01.ccm.0000198525.82124.74. View

18.

Xu H, Chen X, Huang Z . Identification of ESM1 overexpressed in head and neck squamous cell carcinoma. Cancer Cell Int. 2019; 19:118. PMC: 6498655. DOI: 10.1186/s12935-019-0833-y. View

19.

Garcia-Moreno A, Lopez-Dominguez R, Villatoro-Garcia J, Ramirez-Mena A, Aparicio-Puerta E, Hackenberg M . Functional Enrichment Analysis of Regulatory Elements. Biomedicines. 2022; 10(3). PMC: 8945021. DOI: 10.3390/biomedicines10030590. View

20.

Szklarczyk D, Gable A, Lyon D, Junge A, Wyder S, Huerta-Cepas J . STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018; 47(D1):D607-D613. PMC: 6323986. DOI: 10.1093/nar/gky1131. View